ICON Public Limited (NASDAQ:ICLR - Free Report) - Equities researchers at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for ICON Public in a report released on Tuesday, January 14th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $13.44 per share for the year, down from their prior forecast of $13.98. The consensus estimate for ICON Public's current full-year earnings is $13.41 per share. Leerink Partnrs also issued estimates for ICON Public's FY2026 earnings at $15.67 EPS and FY2027 earnings at $17.73 EPS.
Several other brokerages have also recently weighed in on ICLR. TD Cowen dropped their price objective on ICON Public from $369.00 to $285.00 and set a "buy" rating for the company in a report on Friday, October 25th. StockNews.com cut shares of ICON Public from a "buy" rating to a "hold" rating in a research report on Thursday, September 19th. Baird R W lowered shares of ICON Public from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 24th. Truist Financial reaffirmed a "buy" rating and set a $284.00 price target (down previously from $295.00) on shares of ICON Public in a report on Wednesday, December 18th. Finally, Leerink Partners reissued an "outperform" rating and issued a $255.00 price objective (down from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $287.00.
Read Our Latest Stock Analysis on ICLR
ICON Public Price Performance
Shares of NASDAQ ICLR traded down $4.02 during midday trading on Friday, reaching $198.45. The company's stock had a trading volume of 663,941 shares, compared to its average volume of 1,013,631. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The company has a market cap of $16.37 billion, a P/E ratio of 22.15, a P/E/G ratio of 1.59 and a beta of 1.20. The business's 50 day moving average price is $210.05 and its two-hundred day moving average price is $269.05. ICON Public has a fifty-two week low of $183.38 and a fifty-two week high of $347.72.
ICON Public (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter last year, the firm earned $3.10 earnings per share. The business's revenue for the quarter was down 1.2% compared to the same quarter last year.
Institutional Trading of ICON Public
Hedge funds and other institutional investors have recently made changes to their positions in the company. Foyston Gordon & Payne Inc acquired a new stake in ICON Public during the 3rd quarter worth approximately $11,672,000. Icon Wealth Advisors LLC lifted its holdings in shares of ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company's stock worth $3,797,000 after purchasing an additional 11,840 shares during the period. Sara Bay Financial bought a new stake in shares of ICON Public in the third quarter worth $1,143,000. Whittier Trust Co. increased its holdings in ICON Public by 12.3% in the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company's stock valued at $1,155,000 after purchasing an additional 441 shares during the period. Finally, GAMMA Investing LLC raised its position in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock worth $91,000 after purchasing an additional 169 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.
About ICON Public
(
Get Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also
Before you consider ICON Public, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICON Public wasn't on the list.
While ICON Public currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
